Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $1.93 Consensus Target Price from Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been assigned a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $1.93.

Separately, D. Boral Capital lowered their target price on shares of Carisma Therapeutics from $12.00 to $1.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st.

Carisma Therapeutics Price Performance

Shares of NASDAQ:CARM opened at $0.23 on Thursday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $9.48 million, a PE ratio of -0.15 and a beta of 1.63. Carisma Therapeutics has a twelve month low of $0.14 and a twelve month high of $1.90. The company has a 50-day moving average price of $0.20 and a two-hundred day moving average price of $0.39.

Carisma Therapeutics (NASDAQ:CARM) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The firm had revenue of $3.65 million during the quarter, compared to the consensus estimate of $2.47 million. Equities analysts forecast that Carisma Therapeutics will post -1.32 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Carisma Therapeutics stock. Renaissance Technologies LLC grew its holdings in shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) by 11.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 231,357 shares of the company’s stock after buying an additional 24,600 shares during the period. Renaissance Technologies LLC owned 0.55% of Carisma Therapeutics worth $97,000 as of its most recent SEC filing. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.